HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei

Dignam, J. D., Lebovitz, R. M., & Roeder, R. G. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.5.1475 · Cited by 11,262

Sequence and structure-based prediction of eukaryotic protein phosphorylation sites

Blom, N., Gammeltoft, S., & Brunak, S. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3310 · Cited by 3,212

The ErbB signaling network: receptor heterodimerization in development and cancer

Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,489

Molecular determinants of resistance to antiandrogen therapy

Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964

Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB

Yamamoto, K. K., Gonzalez, G. A., Biggs, W., & Montminy, M. (1988) · Nature · doi:10.1038/334494a0 · Cited by 1,281

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 952

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938

Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer

Bryzgunova, O. E., Zaporozhchenko, I. A., Lekchnov, E. A., Амелина, Е. Л., Konoshenko, M. Y., Yarmoschuk, S. V., Pashkovskaya, O. A., Жеравин, А. А., Pak, S. V., RYKOVA, E. Y., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215003 · Cited by 22

CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4

Conrad, H., Gebhard, K., Krönig, H., Neudorfer, J., Busch, D. H., Peschel, C., & Bernhard, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8135 · Cited by 22

The Clinicopathologic Features of Molecular Apocrine Breast Cancer

Cha, Y. J., Jung, W.-H., & Koo, J. S. (2012) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2012.46.2.169 · Cited by 21

The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells

Hsu, F.-N., Yang, M.-S., Lin, E., Tseng, C.-F., & Lin, H. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00610.2010 · Cited by 21

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer

Armstrong, C. M., & Gao, A. C. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.001 · Cited by 21

Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model

Ilagan, R., Zhang, L. J., Pottratz, J., Le, K., Salas, S. J., Iyer, M. R., Wu, L., Gambhir, S. S., & Carey, M. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0197 · Cited by 21

Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult

Hess-Wilson, J. K., Daly, H. K., Zagórski, W., Montville, C. P., & Knudsen, K. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2249 · Cited by 21

Metabolic Control of Sensory Neuron Survival by the p75 Neurotrophin Receptor in Schwann Cells

Follis, R. M., Tep, C., Genaro‐Mattos, T. C., Kim, M. L., Ryu, J. C., Morrison, V. E., Chan, J. R., Porter, N. A., Carter, B. D., & Yoon, S. O. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.3243-20.2021 · Cited by 17

Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression

Wang, G., Haile, S., Comuzzi, B., Tien, A. H., Wang, J., Yong, T. M. K., Jelescu-Bodos, A. E., Blaszczyk, N., Vessella, R. L., Masri, B. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3506 · Cited by 19

AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer

Liu, D. (2020) · Cellular Oncology · doi:10.1007/s13402-019-00492-6 · Cited by 19

Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells

Farooqı, A. A., Hou, M., Chen, C., Wang, C., & Chang, H. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-34 · Cited by 18

Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling

Bratland, Å., Boender, P. J., Høifødt, H. K., Østensen, I. H. G., Ruijtenbeek, R., Wang, M. Y., Berg, J. P., Lilleby, W. A., Fodstad, Ø., & Ree, A. H. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9248-9 · Cited by 19

EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells.

Zhou, H., Zhang, Y., & Hamburger, A. W. (2011) · PubMed · Cited by 19

Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data

Lozano, J., Soler, M., Bermudo, R., Abia, D., Fernandez, P., Thomson, T., & Ortiz, A. (2005) · BMC Genomics · doi:10.1186/1471-2164-6-109 · Cited by 19

Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling

Hu, J., Zhu, W., Wei, B., Wen, H., Mao, S., Xu, H., Hu, M., Yang, T., & Jiang, H. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000420 · Cited by 18

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

Anastasopoulou, E. A., Voutsas, I. F., Keramitsoglou, T., Gouttefangeas, C., Kalbacher, H., Thanos, A., Papamichail, M., Perez, S. A., & Baxevanis, C. N. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1717-1 · Cited by 18

The androgen receptor in hormone-refractory prostate cancer

Mao, H., Zhu, Z., & Chen, C. D. (2008) · Asian Journal of Andrology · doi:10.1038/aja.2008.14 · Cited by 18

The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center

Mayer, M., Wolber, P., Prinz, J., Jansen, L., Eßer, J., Shabli, S., Quaas, A., Klußmann, J. P., Sharma, S. J., Nachtsheim, L., et al. (2024) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-024-08627-8 · Cited by 17

To Die or to Survive, a Fatal Question for the Destiny of Prostate Cancer Cells after Androgen Deprivation Therapy

Zhang, K., Firus, J., Prieur, B., Jia, W. W.-G., & Rennie, P. S. (2011) · Cancers · doi:10.3390/cancers3021498 · Cited by 18

Intracellular adaptor molecules and AR signalling in the tumour microenvironment

Reebye, V., Frilling, A., Habib, N. A., & Mintz, P. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.11.019 · Cited by 17

Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions

Mitsiades, N., & Bedoya (2013) · OncoTargets and Therapy · doi:10.2147/ott.s24941 · Cited by 16

Genomic and epigenomic alterations in prostate cancer

Aschelter, A. M., Giacinti, S., Caporello, P., & Marchetti, P. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00128 · Cited by 16

Precision medicine for prostate cancer

Galazi, M., Rodríguez‐Vida, A., Ng, T., MASON, M. D., & Chowdhury, S. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.972948 · Cited by 16

Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression

Rosestedt, M., Andersson, K. G., Mitran, B., Rinne, S. S., Максимилианович, Т. В., Löfblom, J., Orlova, A., & Ståhl, S. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4152 · Cited by 15

Microenvironment-Mediated Resistance to Anti-Androgen Therapy

Orme, J. J., & Huang, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.007 · Cited by 15

Clustering microarray-derived gene lists through implicit literature relationships

Burkart, M. F., Wren, J. D., Herschkowitz, J. I., Perou, C. M., & Garner, H. R. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm261 · Cited by 15

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer

Tsai, C.-H., Tzeng, S., Hsieh, S.-C., Tsai, C.-J., Yang, Y., Tsai, M., & Hsiao, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00721 · Cited by 14

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients

McCall, P., Adams, C. E., Willder, J. M., Bennett, L., Qayyum, T., Orange, C., Underwood, M., & Edwards, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816656 · Cited by 14

Beyond Androgen Deprivation

McCarty, M. F., Hejazi, J., & Rastmanesh, R. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414534728 · Cited by 14

Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?

Srivastava, T. P., Dhar, R., & Karmakar, S. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-024-01338-z · Cited by 13

New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors

Bousset, L., Rambur, A., Fouache, A., Buñay, J., Morel, L., Lobaccaro, J. A., Baron, S., Trousson, A., & de Joussineau, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092545 · Cited by 14

Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial

Nadal, R., Taplin, M., & Joaquim Bellmunt, B. (2014) · Future Oncology · doi:10.2217/fon.13.275 · Cited by 13

Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: A possible radioimmunotherapy to prostate carcinoma

Wang, H., Lin, W., Chen, M., Lin, T. P., Chao, C.-H., Hsu, F.-N., Lin, E., Huang, C., Luo, T., & Lin, H. (2013) · International Journal of Radiation Biology · doi:10.3109/09553002.2013.762136 · Cited by 13

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

Voutsas, I. F., Anastasopoulou, E. A., Tzonis, P., Papamichail, M., Perez, S. A., & Baxevanis, C. N. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0183-4 · Cited by 13

Androgen Receptor Overexpression Is Neuroprotective in Experimental Stroke

Ayala, P., Uchida, M., Akiyoshi, K., Cheng, J., Hashimoto, J. G., Jia, T., Rønnekleiv, O. K., Murphy, S. J., Wiren, K. M., & Hurn, P. D. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0079-z · Cited by 12

Improving selective androgen receptor modulator discovery and preclinical evaluation

Jones, J. O. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903206957 · Cited by 12

G‐protein alpha‐s and ‐12 subunits are involved in androgen‐stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells

Liu, J., Youn, H., Yang, J., Du, N., Liu, J., Liu, H., & Li, B. (2011) · The Prostate · doi:10.1002/pros.21345 · Cited by 12

Her2/neu Expression by Reverse Transcriptase-Polymerase Chain Reaction in the Peripheral Blood of Prostate Cancer Patients

Fantinato, A. P., Tobias‐Machado, M., Fonseca, F. L. A., Pinto, J. L. F., Wroclawski, M. L., Wroclawski, E. R., Verotti, M. J., & del Giglio, A. (2007) · Tumori Journal · doi:10.1177/030089160709300510 · Cited by 12

Differential regulation of the androgen receptor by protein phosphatase regulatory subunits

Grey, J., Jones, D. L., Wilson, L., Nakjang, S., Clayton, J., Temperley, R., Clark, E., Gaughan, L., & Robson, C. N. (2017) · Oncotarget · doi:10.18632/oncotarget.22883 · Cited by 13

ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature

Vellky, J. E., Kirkpatrick, B. J., Gutgesell, L. C., Morales, M., Brown, R. M., Wu, Y., Maienschein‐Cline, M., Notardonato, L. D., Weinfeld, M. S., Nguyen, R. H.-T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2161 · Cited by 11

New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours

Iggo, R. D. (2011) · Breast Cancer Research · doi:10.1186/bcr3036 · Cited by 11

Profiling serum HER-2/NEU in prostate cancer.

Σιαμπανοπούλου, Μ., Galaktidou, G., Dimasis, N., & Gotzamani‐Psarrakou, A. (2013) · Europe PMC (PubMed Central) · Cited by 11

Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC)

Jonnalagadda, B., Arockiasamy, S., & Krishnamoorthy, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118208 · Cited by 11

Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells

Fonseca‐Alves, C. E., Leis‐Filho, A. F., Lacerda, Z. A., Lainetti, P. D. F., Amorim, R. L., & Rogatto, S. R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297043 · Cited by 10

Androgen Receptor Pathway in Salivary Gland Cancer

Ho, A. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01983 · Cited by 10

Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women

Singh, L. C., Chakraborty, A., Mishra, A. K., Devi, T. R., Sugandhi, N., Chintamani, C., Bhatnagar, D., Kapur, S., & Saxena, S. (2011) · Medical Oncology · doi:10.1007/s12032-011-9952-6 · Cited by 10

Inhibition of the Androgen Receptor Activity by Coprinus comatus Substances

Dotan, N., Wasser, S. P., & Mahajna, J. A. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.607542 · Cited by 10

Androgen receptor (AR) inhibitor ErbB3-binding protein-1 (Ebp1) is not targeted by the newly identified AR controlling signaling axis heat-shock protein HSP27 and microRNA miR-1 in prostate cancer cells

Stope, M. B., Peters, S., Großebrummel, H., Zimmermann, U., Walther, R., & Burchardt, M. (2014) · World Journal of Urology · doi:10.1007/s00345-014-1307-4 · Cited by 9

Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment

Zhang, L., Davis, J. S., Zelivianski, S., Lin, F., Schutte, R., Davis, T. L., Hauke, R. J., Batra, S. K., & Lin, M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.041 · Cited by 8

Molecular genetic mechanisms of drug resistance in prostate cancer

Krasnov, G. S., Dmitriev, A. A., Садритдинова, А. Ф., Волченко, Н. Н., Slavnova, E. N., Данилова, Т. В., Snezhkina, A. V., Melnikova, N. V., Fedorova, M., Lakunina, V. A., et al. (2015) · Molecular Biology · doi:10.1134/s0026893315050118 · Cited by 8

EGFR family heterodimers in cancer pathogenesis and treatment

Stern, H. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_2 · Cited by 8

Current and potential targets for drug design in the androgen receptor pathway for prostate cancer

Guddati, A. K. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1455662 · Cited by 7

Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer

Goulielmaki, M., Stokidis, S., Anagnostou, T., Voutsas, I. F., Gritzapis, A. D., Baxevanis, C. N., & Fortis, S. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065954 · Cited by 7

Recepteur d'origine nantais (RON), more than a kinase: Role in castrate‐resistant prostate cancer

Batth, I. S., Yun, H., & Kumar, A. P. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22354 · Cited by 7

Молекулярно-генетические механизмы формирования лекарственной устойчивости при терапии рака предстательной железы

Krasnov, G. S., Dmitriev, A. A., Садритдинова, А. Ф., Волченко, Н. Н., Slavnova, E. N., Данилова, Т. В., Snezhkina, A. V., Melnikova, N. V., Fedorova, M., Lakunina, V. A., et al. (2015) · Molecular Biology · doi:10.7868/s0026898415050110 · Cited by 8

Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells

Inoue, T., Kobayashi, T., Terada, N., Shimizu, Y., Kamoto, T., Ogawa, O., & Nakamura, E. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.5.689 · Cited by 9

HER2 as a molecular trojan horse in prostate cancer: mechanistic insights and therapeutic unlocks

Mukherjee, A. G., & Gopalakrishnan, A. V. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11202-x · Cited by 6

The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells

Awasthi, S., Ezelle, H. J., Hassel, B. A., & Hamburger, A. W. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2409-z · Cited by 6

Modelling synergistic interactions between HER2, Sprouty2 and PTEN in driving prostate carcinogenesis

Ahmad, I., Gao, M., Patel, R., & Leung, H. Y. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.40 · Cited by 6

GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells

Hao, J., Ci, X., Wang, Y., Choi, S. Y. C., Sullivan, S. E., Xue, H., Wu, R., Dong, X., Haegert, A. M., Collins, C. C., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33335 · Cited by 6

Breast Carcinoma

Bandyopadhyay, S., & Ali‐Fehmi, R. (2013) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.08.009 · Cited by 6

New Insights into Prostate Cancer Biology

Balakumaran, B. S., & Febbo, P. G. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.06.005 · Cited by 6

Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation

Jia, Z. (2012) · Journal of Data Mining in Genomics & Proteomics · doi:10.4172/2153-0602.1000e102 · Cited by 5

Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression

Maassarani, M. E., Barbarin, A., Fromont, G., Kaissi, O., Lebbe, M., Vannier, B., Moussa, A., & Seité, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155950 · Cited by 6

Bicalutamide Demonstrates Biologic Effectiveness in Prostate Cancer Cell Lines and Tumor Primary Cultures Irrespective of Her2/neu Expression Levels

Gravina, G. L., Festuccia, C., Millimaggi, D., Tombolini, V., Dolo, V., Vicentini, C., & Bologna, M. (2009) · Urology · doi:10.1016/j.urology.2009.01.018 · Cited by 5

PTEN in Prostate Cancer

Ruscetti, M. A., & Wu, H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_4 · Cited by 6

Androgen-dependent regulation of Her-2/neu in prostate cancer cells

Berger, R., Lin, D., Nieto, M., Signoretti, S., Hahn, W. C., & Loda, M. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10099 · Cited by 5

The molecular basis of prostate cancer

Olsson, A. Y., & Cooper, C. S. (2005) · British Journal of Hospital Medicine · doi:10.12968/hmed.2005.66.11.20021 · Cited by 4

Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionPreprint

Wilkinson, S. C., Ku, A. T., Lis, R. T., King, I. M., Low, D., Trostel, S. Y., Bright, J. R., Terrigino, N. T., Baj, A., Fenimore, J. M., et al. (2024) · medRxiv · doi:10.1101/2024.02.09.24302395 · Cited by 4

Cell Biology of Prostate Cancer and Molecular Targets

Gleave, M. E., Cox, M., & Wang, Y. Z. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_1 · Cited by 3

Signal Transduction by the Ras–MAP Kinase Pathway in Prostate Cancer Progression

Gioeli, D. G., Kraus, S. R., & Weber, M. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-079-3_11 · Cited by 3

What controls PTEN and what it controls (in prostate cancer)

Ghosh, P. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2011.122 · Cited by 2

Autocrine amphiregulin signaling sustains castration-resistant Ly6d+ prostate cancer cells

Xin, L. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.05.011 · Cited by 2

El cáncer de próstata resistente a castración. Mecanismos de progresión y nuevos tratamientos

Soria, A. M., Carda, C. L., López, A. B., & Hernández, J. G. (2012) · Revista Cubana de Urología · Cited by 2

Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates

Lilleby, W. A., Solca, F., & Redalen, K. R. (2010) · Oncology Reviews · doi:10.1007/s12156-010-0070-z · Cited by 2

Androgen Receptor Biology in Prostate Cancer

Gelmann, E. P. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_5 · Cited by 2

Docetaxel Based Treatment for Metastatic Castration-Resistant Prostate Cancer-our Early Experience

Ghagane, S. C., & Nerli, R. B. (2016) · Translational Biomedicine · doi:10.21767/2172-0479.100070 · Cited by 2

The Role of Androgen Receptor in Prostate Cancer

Berger, A., & Rickman, D. S. (2017) · Molecular pathology library · doi:10.1007/978-3-319-64096-9_20 · Cited by 2

Molecular Progression of Prostate Cancer: Androgens and Estrogens

Boorjian, S. A., & Tindall, D. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-259-9_7 · Cited by 2

Prostate Molecular Oncogenesis

Gelmann, E. P. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-079-3_4 · Cited by 1

Bases de biologie moléculaire du cancer de la prostate résistant à la castration

Doucet, L. S., Terrisse, S. A., Gauthier, H., Pouessel, D., Maignan, C. L., Teixeira, L., & Culine, S. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.04.014 · Cited by 1

The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities

Wu, B. J., & Chung, L. W. K. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_9 · Cited by 1

Resistance to PI3K Pathway Inhibition

Shah, P. D., & Chandarlapaty, S. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_5 · Cited by 1

Novel Approaches to Androgen Receptor Blockade

Mellinghoff, I. K. (2006) · Translational medicine series · doi:10.3109/9781420019858.010 · Cited by 1

HISTORY OF CANCER HORMONOTHERAPY

Abduloeva, N. K., Scriabin, M. V., Skripko, О. А., Kaitova, S. K., Ryandjina, R. A., Kazakova, К. N., & Моисеенко, В. (2023) · Practical oncology · doi:10.31917/2402105 · Cited by 1

Apocrine carcinoma of the breast: Review

Yang, C., Wang, Z. I., & Yen, Y. (2022) · Forum of Clinical Oncology · doi:10.2478/fco-2023-0007 · Cited by 1

Stratifying Cancer Therapies by Molecular Interactions and Imaging

Galazi, M., Weitsman, G. E., Monypenny, J., Coban, O., Milewicz, H., Gómez, V., Ciccarelli, F. D., & Ng, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_15 · Cited by 1

Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University Curriculum vitae and Bibliography

Mellinghoff, I. K. (2014) · Cited by 1

Developing androgen receptor targeting for salivary gland cancers

Ho, A. L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy042 · Cited by 1

Transcriptional Inactivation of TP53 and the BMP Pathway Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate CancerPreprint

Han, H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2021) · Research Square · doi:10.1101/2021.04.14.439569 · Cited by 1

Intercellular Targets of Prostate Cancer

Whang, Y. E., & George, D. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-224-3_25 · Cited by 1

Identification and Targeting of Upstream Tyrosine Kinases Mediating PI3 Kinase Activation in PTEN-Deficient Prostate Cancer

Balk, S. P. (2009) · doi:10.21236/ada510490

Interrogating Androgen Receptor Mediated Gene Expression and Tumor Progression by Molecular Imaging

Carey, M. (2003) · doi:10.21236/ada419790

Androgen Metabolism in Progression to Androgen-Independent Prostate Cancer

Balk, S. P. (2008) · doi:10.21236/ada502868

FUNCTION OF ANDROGEN RECEPTOR IN PROSTATE CANCER EPITHELIAL MESENCHYMAL TRANSITION AND MICROTUBULE TARGETING

Zhu, M. (2010) · UKnowledge (University of Kentucky)

Abstract IA4: Reciprocal feed-back regulation of the PI3K and AR pathways in prostate cancer: A mechanism of innate resistance

Carver, B. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.mechres-ia4

S86 Results from the first phase I clinical study of the novel Ii-Key/HER-2(776–790) hybrid peptide vaccine in patients with prostate cancer

Mpisias, S., Kalogeropoulos, T., Koutsiaris, E. A., Rempelakos, A., Konandreas, A., Georgakopoulou, K., Perez, S. A., Baxevanis, K., Arvanitakis, T., & Thanos, A. (2009) · European Urology Supplements · doi:10.1016/s1569-9056(09)74967-x

Abstract B237: Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

Oh, S. J., Erb, H. H. H., Hobisch, A., Santer, F. R., & Čulig, Z. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-b237

ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian))

Awasthi, S., & Hamburger, A. (2012) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/48356

Role of androgen receptor in folate receptor α regulation and in prostate cancer

Sivakumaran, S. (2012) · OhioLink ETD Center (Ohio Library and Information Network)

Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer

Liu, Y., Majumder, S., McCall, W., Sartor, C. I., Mohler, J. L., Gregory, C. W., Earp, H. S., & Whang, Y. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4292 · Cited by 99

Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor

Sugita, S., Kawashima, H., Tanaka, T., Kurisu, T., Sugimura, K., & Nakatani, T. (2004) · Oncology Reports · doi:10.3892/or.11.6.1273 · Cited by 21

HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

Wen, Y., Hu, M. C. ‐., Makino, K., Spohn, B., Bartholomeusz, G. A., Yan, D., & Hung, M. (2000) · PubMed · Cited by 461

HER2/HER3 heterodimers in prostate cancer

Freeman, M. R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.018 · Cited by 25

Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells

Berger, R., Lin, D. I., Nieto, M., Sicińska, E., Garraway, L. A., Adams, H., Signoretti, S., Hahn, W. C., & Loda, M. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3928 · Cited by 79